You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 398 AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy

Citation Tools

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
398 AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
O’Day S, khoueiry AE, Ramamurthy C, et al
398 AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy
Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0398